| Document Date: 2012-10-26 01:56:33
Open Document File Size: 80,72 KBShare Result on Facebook
City New York / Paris / Tokyo / Nagoya / / Company Sanofi K.K. / Chugai Pharmaceutical Co. Ltd. / Kowa Company Ltd. / Translation Chugai Pharmaceutical Co. Ltd. / Genzyme / Kowa Pharmaceutical Co. Ltd. / Kamakura / Chugai Pharma Europe / Chugai Pharma / Gotemba / Tokyo Stock Exchange / / Continent Europe / / Country France / Japan / United States / / Currency JPY / / Event Business Partnership / Company Listing Change / FDA Phase / / IndustryTerm biotechnology products / technology development / machinery / treatment of cardiovascular diseases / chemical products / healthcare / pharmaceuticals / prescription pharmaceuticals / research-based pharmaceutical / cotton wholesaler / therapeutic solutions / consumer healthcare / manufacturing / pharmaceutical products / green products / diabetes treatment / diabetes solutions / / MedicalCondition arteriosclerosis / diabetic neuropathy / hypoglycemia / cardiovascular diseases / diabetic retinopathy / serious diseases / diabetic nephropathy / hypertension / atherosclerosis / dyslipidemia / diabetes / lifestyle diseases / diabetes mellitus / inflammation / hypercholesterolemia / / MedicalTreatment amputation / dialysis / / Organization Ministry of Health / / Person Osamu Nagayama / Yoshihiro Miwa / / / Position cotton wholesaler / global and diversified healthcare leader / CEO / trusted healthcare leader / President & CEO / Chairman & CEO / / Product Japan / / Technology biotechnology / therapeutic solutions / pharmaceutical products / SAN / dialysis / pharmaceutical / / URL http /
SocialTag |
License Agreement of SGLT2 Inhibitor “CSG452” in Japan